**Core Concept**
The mechanism of action of **Ticagrelor** involves the inhibition of **platelet activation** and **aggregation**. This is crucial in the prevention of **thrombotic events** such as myocardial infarction and stroke. **Ticagrelor** belongs to a class of drugs known as **P2Y12 receptor inhibitors**.

**Why the Correct Answer is Right**
**Ticagrelor** works by irreversibly binding to the **P2Y12 receptor** on the surface of **platelets**, preventing the binding of **adenosine diphosphate (ADP)**. This inhibition of **ADP** binding prevents the activation of the **P2Y12 receptor**, which in turn inhibits **platelet activation** and **aggregation**. This mechanism is essential for the prevention of **thrombotic events**.

**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect because **Ticagrelor** does not work by inhibiting **phosphodiesterase**.
**Option B:** Incorrect because **Ticagrelor** does not work by blocking **thromboxane A2 receptors**.
**Option D:** Incorrect because **Ticagrelor** does not work by inhibiting **glycoprotein IIb/IIIa**.

**Clinical Pearl / High-Yield Fact**
**Ticagrelor** is a **reversible** inhibitor of **P2Y12 receptors**, which distinguishes it from older **irreversible** inhibitors like **Clopidogrel**. This reversibility contributes to its **faster onset** and **offset** of action.

**Correct Answer:** D. Ticagrelor is a P2Y12 receptor inhibitor.